A matter has come to my attention that I would appreciate having the opportunity of addressing through the pages of the Archives. The issue relates to our article1 on the neuropsychological test battery (NTB) published in September 2007 and my consulting relationship with Elan Pharmaceuticals and Wyeth Research. Let me begin by clarifying my financial position regarding the NTB:
Harrison J. Notice of Failure to Disclose Financial Interest: “A Neuropsychological Test Battery for Use in Alzheimer Disease Clinical Trials” (Arch Neurol. 2007;64:1323-1329). Arch Neurol. 2008;65(7):992–996. doi:10.1001/archneur.65.7.992-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: